MX2022000854A - Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. - Google Patents
Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.Info
- Publication number
- MX2022000854A MX2022000854A MX2022000854A MX2022000854A MX2022000854A MX 2022000854 A MX2022000854 A MX 2022000854A MX 2022000854 A MX2022000854 A MX 2022000854A MX 2022000854 A MX2022000854 A MX 2022000854A MX 2022000854 A MX2022000854 A MX 2022000854A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- alkyl
- substituted
- compounds
- formula
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100023921 Serine/threonine-protein kinase ATR Human genes 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen compuestos con la fórmula (I) o sales farmacéuticamente aceptables de estos, en donde - es un enlace simple, y cada Y es N o CR4; o - está ausente, y cada Y es NRY, carbonilo o (C(RY)2, en donde cada R1 es H o alquilo de C1-6 opcionalmente sustituido; R1 es alquilo de C1-6 opcionalmente sustituido o H; R3 es heteroarilo de C1-9 opcionalmente sustituido o alquilo de C1-6 heteroarilo de C1-9 opcionalmente sustituido; cada R4 es hidrógeno, halógeno, alquilo de C1-6 opcionalmente sustituido, alquenilo de C2-6 opcionalmente sustituido o alquinilo de C2-6 opcionalmente sustituido; X es hidrógeno o halógeno; y R2 es como se define en la reivindicación 1. También se describen composiciones farmacéuticas que contienen los compuestos con la fórmula (I) y métodos para su preparación. Los compuestos con la fórmula (I) pueden ser inhibidores de la proteína cinasa relacionada con ataxia telangiectasia y RAD-3 (ATR) y usarse para el tratamiento de enfermedades y afecciones tales como cánceres.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962877177P | 2019-07-22 | 2019-07-22 | |
| PCT/CA2019/051539 WO2020087170A1 (en) | 2018-10-30 | 2019-10-30 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |
| PCT/CA2020/051014 WO2021012049A1 (en) | 2019-07-22 | 2020-07-22 | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000854A true MX2022000854A (es) | 2022-02-10 |
Family
ID=74192632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000854A MX2022000854A (es) | 2019-07-22 | 2020-07-22 | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220185809A1 (es) |
| EP (1) | EP4003993A4 (es) |
| JP (2) | JP7617076B2 (es) |
| KR (1) | KR20220035925A (es) |
| CN (1) | CN114174292B (es) |
| AU (1) | AU2020317381A1 (es) |
| BR (1) | BR112022000431A2 (es) |
| CA (1) | CA3148278A1 (es) |
| CO (1) | CO2022001853A2 (es) |
| CR (1) | CR20220068A (es) |
| EC (1) | ECSP22012347A (es) |
| IL (1) | IL289763A (es) |
| MX (1) | MX2022000854A (es) |
| PH (1) | PH12022550156A1 (es) |
| UA (1) | UA129807C2 (es) |
| WO (1) | WO2021012049A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210097124A (ko) | 2018-10-30 | 2021-08-06 | 리페어 세라퓨틱스 인크. | 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법 |
| AU2020317381A1 (en) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc. | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors |
| KR20220128350A (ko) * | 2019-12-11 | 2022-09-20 | 리페어 세라퓨틱스 인크. | Parp 억제제와 조합되는 atr 억제제의 용도 |
| WO2022226655A1 (en) * | 2021-04-28 | 2022-11-03 | Repare Therapeutics Inc. | Methods of treating cancers having a biallelic loss of function or gene overexpression mutation |
| US20240294521A1 (en) * | 2021-06-04 | 2024-09-05 | Repare Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| CN115677730B (zh) * | 2021-07-27 | 2024-11-12 | 励缔(杭州)医药科技有限公司 | 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途 |
| CN113856764B (zh) * | 2021-10-29 | 2022-11-01 | 华中科技大学 | 一种过渡金属催化剂及其制备方法和应用 |
| CN116099390B (zh) * | 2022-11-14 | 2024-07-23 | 石河子大学 | 一种混合维度材料PNT@NiCo-LDH及其制备方法与应用 |
| EP4688778A1 (en) * | 2023-04-07 | 2026-02-11 | Biogen MA Inc. | 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025067111A1 (zh) * | 2023-09-27 | 2025-04-03 | 苏州必扬医药科技有限公司 | 一种Menin-MLL相互作用抑制剂及其制备方法和应用 |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025181153A1 (en) * | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025239794A1 (en) * | 2024-05-15 | 2025-11-20 | Joint Stock Company “Biocad” | Ataxia telangiectasia and rad3-related inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20130375A1 (es) * | 2009-12-31 | 2013-04-10 | Hutchison Medipharma Ltd | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos |
| ES2528269T3 (es) * | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| EP2681216B1 (en) * | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9073924B2 (en) * | 2011-09-13 | 2015-07-07 | Glaxosmithkline Llc | Azaindazoles |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| US8906910B2 (en) * | 2011-12-20 | 2014-12-09 | Glaxosmithkline Llc | Imidazopyridine derivatives as PI3 kinase |
| TWI700283B (zh) * | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| UY36654A (es) * | 2015-04-29 | 2016-10-31 | Janssen Pharmaceutica Nv | Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen |
| WO2017121684A1 (en) * | 2016-01-14 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| KR20210097124A (ko) * | 2018-10-30 | 2021-08-06 | 리페어 세라퓨틱스 인크. | 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법 |
| AU2020317381A1 (en) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc. | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors |
-
2020
- 2020-07-22 AU AU2020317381A patent/AU2020317381A1/en active Pending
- 2020-07-22 BR BR112022000431A patent/BR112022000431A2/pt unknown
- 2020-07-22 UA UAA202200734A patent/UA129807C2/uk unknown
- 2020-07-22 CR CR20220068A patent/CR20220068A/es unknown
- 2020-07-22 KR KR1020227004829A patent/KR20220035925A/ko active Pending
- 2020-07-22 PH PH1/2022/550156A patent/PH12022550156A1/en unknown
- 2020-07-22 CA CA3148278A patent/CA3148278A1/en active Pending
- 2020-07-22 MX MX2022000854A patent/MX2022000854A/es unknown
- 2020-07-22 EP EP20843290.6A patent/EP4003993A4/en active Pending
- 2020-07-22 CN CN202080052942.8A patent/CN114174292B/zh active Active
- 2020-07-22 WO PCT/CA2020/051014 patent/WO2021012049A1/en not_active Ceased
- 2020-07-22 JP JP2022504181A patent/JP7617076B2/ja active Active
-
2022
- 2022-01-11 IL IL289763A patent/IL289763A/en unknown
- 2022-01-20 US US17/580,207 patent/US20220185809A1/en active Pending
- 2022-02-16 EC ECSENADI202212347A patent/ECSP22012347A/es unknown
- 2022-02-22 CO CONC2022/0001853A patent/CO2022001853A2/es unknown
-
2025
- 2025-01-06 JP JP2025001996A patent/JP7758895B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021012049A8 (en) | 2021-04-15 |
| BR112022000431A2 (pt) | 2022-03-03 |
| IL289763A (en) | 2022-03-01 |
| UA129807C2 (uk) | 2025-08-06 |
| US20220185809A1 (en) | 2022-06-16 |
| CR20220068A (es) | 2022-06-30 |
| EP4003993A4 (en) | 2023-01-18 |
| CO2022001853A2 (es) | 2022-03-29 |
| JP7758895B2 (ja) | 2025-10-22 |
| WO2021012049A1 (en) | 2021-01-28 |
| JP7617076B2 (ja) | 2025-01-17 |
| KR20220035925A (ko) | 2022-03-22 |
| JP2025061048A (ja) | 2025-04-10 |
| AU2020317381A1 (en) | 2022-02-10 |
| CN114174292B (zh) | 2024-06-18 |
| CA3148278A1 (en) | 2021-01-28 |
| EP4003993A1 (en) | 2022-06-01 |
| PH12022550156A1 (en) | 2023-05-08 |
| ECSP22012347A (es) | 2022-03-31 |
| CN114174292A (zh) | 2022-03-11 |
| JP2022541825A (ja) | 2022-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22012347A (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr | |
| PE20230825A1 (es) | Inhibidores de kras triciclicos fusionados | |
| AR130689A1 (es) | Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos | |
| UY26968A1 (es) | Agentes terapéuticos | |
| GEP20207202B (en) | Tyrosine amide derivatives as rho-kinase inhibitors | |
| ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| NO331166B1 (no) | Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene | |
| NO20073357L (no) | 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| PL378136A1 (pl) | Pirymidyny i triazyny hamujące replikacją wirusa HIV | |
| ZA202002762B (en) | Benzimidazole derivatives and their uses | |
| AR040580A1 (es) | Derivados de pirazol heterobiciclico como inhibidores de la quinasa | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| MX2024013019A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX389581B (es) | Compuestos que contienen nitrogeno sustituido. | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
| TR200103789T2 (tr) | Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller. | |
| DOP2020000088A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. |